Introduction
transplants and cyclosporine [ 1] . Co-administration of the antihypertensive calcium channel blocker diltiazem has several advantages. It reduces the incidence of both Today the undecapeptide cyclosporine (SandimmunA, Sandoz, Basle, Switzerland) is the major immunograft failure and graft rejection episodes [2-4 ]; several mechanisms have been described such as protection of suppressant after kidney transplantation. Hypertension is a frequent complication of patients receiving kidney the renal arterioles against cyclosporine-induced thicken- survival in rats [7 ] . In vitro diltiazem exerts immuno-(mg day−1)
suppressive activity by inhibition of lymphocyte prolifer- and its blood concentration associated toxic side effects, cyclosporine doses have to be adjusted on the basis of its trough blood concentrations. Coadministration of revisions. Patients with infectious diseases, organ rejection, known liver diseases or contraindications to diltiazem and cyclosporine leads to a rise in cyclosporine blood concentrations which requires dose reduction of calcium channel blocker therapy were excluded as well as patients under therapy with drugs known to interact up to 48% [9] [10] [11] . Like diltiazem [12 ] , cyclosporine is metabolised by enzymes of the cytochrome P450 (CYP) with cyclosporine metabolism [16] such as high dosage corticosteroids, other calcium channel blockers, macrol-3A subfamily in the liver [13, 14 ] resulting in more than 30 metabolites [ 15] . In vitro diltiazem proved to be an ide antibiotics, antiepileptics, oral antimycotics, contraceptives, and cimetidine. Patients were treated with effective competitive inhibitor of cyclosporine metabolism [12, 16 ] . Therefore, the increased bioavailability 176±28 mg cyclosporine given twice daily. After randomization in a cross-over fashion, six patients received of cyclosporine in combination with diltiazem could be explained by a competitive interaction of diltiazem with additionally to cyclosporine 90 mg diltiazem twice daily for 1 week while the other six patients continued to the cyclosporine metabolism in the liver. To date, several studies have investigated the pharmacokinetic interaction receive cyclosporine. After 1 week diltiazem was discontinued and the other six patients received 90 mg of diltiazem and cyclosporine [17] [18] [19] [20] , all of which had at least one of the following major drawbacks: patients diltiazem twice daily during the second week of the study. Cyclosporine pharmacokinetics were assessed at taking other drugs known to be CYP3A inhibitors have not been excluded and/or only cyclosporine was measthe end of the first and the second week. At these instances, 12 h urine was collected. During the study ured. A few studies included measurement of single first generation metabolites, that means metabolites which period, cyclosporine and diltiazem doses remained unchanged. None of the patients reported any unwanted were changed in one position, but reported only trough blood concentrations. Meanwhile studies have shown effects, had to be excluded for other reasons or withdrew from the study by own will. The study protocol was that especially second generation metabolites which are generated by further metabolism of first generation approved by the ethics committee of the Medizinische Hochschule Hannover, Hannover, Germany. metabolites, are particularly sensitive to changes of liver function [15 ] . In this study only stable renal graft recipients under cyclosporine immunosuppression without concomitant therapy with other CYP3A substrates Methods were included. Cyclosporine metabolite patterns including first and second generation metabolites were analysed At the end of the first and the second week, blood samples were taken before and 0.5, 1, 1.5, 2, 3, 4, 6, using h.p.l.c. 8 , and 12 h after the morning cyclosporine dose. Cyclosporine and its metabolites AM1, AM9, AM1c, AM19, AM1c9, AM14N, AM1A, AM4N, and AM4N9 were measured by h.p.l.c. as previously described by Methods Christians et al. [21 ] . In brief, cyclosporin D was added to the blood samples as internal standard. The samples Patients were extracted by solid-liquid extraction using C 18 reversed phase glass extraction columns. Cyclosporine Twelve stable renal allograft recipients (six males, six females) were enrolled in this two period cross-over and its metabolites were separated on a 250×4 mm analytical h.p.l.c. column filled with C 18 material of study. The demographic data are shown in Table 1 . Inclusion criteria were a stable physical condition and 3 mm particle size. A concave acetonitrile/water pH 3 gradient was run, the column temperature was set to transplant function, a minimum of 3 months after transplantation (mean±s.d., 12±2.3 months), an age 75°C and the chromatograms were recorded at a u.v.-detector wavelength of 205 nm. For identification and between 18 and 65 years at the beginning of the study, a bodyweight between 50 and 90 kg, stable medication, calibration, cyclosporine metabolites isolated from bile and structurally identified by mass spectrometry and no changes of cyclosporine dosage for at least 3 weeks, normal liver function and a written, informed consent one-and two-dimensional n.m.r.-spectroscopy as previously described [22 ] were used. The Hawk's Cay of the patients after full explanation according to the guidelines of the Declaration of Helsinki and its nomenclature of the cyclosporine metabolites [23 ] was used. Quality assessment during the study gave the following specification for the quantification of cyclosporine: The lower limit of quantification was 25 mg l−1, the range of reliable response was 25-5000 mg l−1, the calibration curve was linear with y=0.97+28 (r=0.99), the recovery was 86±20% for 50 ng samples (n=10) and 71±24% for 500 ng samples (n=10). Intra-assay accuracy was −4.9% for 25 ng samples, −0.5% for 250 ng samples, +3.2% for 500 ng samples and the interassay variation during the study 14.1% for 25 ng samples (n=25) and 6.8% for 250 ng samples (n=25). Pharmacokinetic parameters were calculated using an open two-compartment model using the algorithm implemented in the Topfit pharmacokinetic program (Version 2.0, Gustav-Fischer Verlag, Stuttgart, Germany). Peak blood drug concentrations (C max ), time to peak concentration (t max ), AUC(0, 12 h) and terminal half-life (t 1/2,z ) were calculated after curve fitting using a biexponential distribution function with first-order input. During the study, patients were checked the day before the pharmacokinetic profiles were taken including physical examination and electrocardiographic controls. Liver function (serum bilirubin concentration, activities of alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transpeptidase, alkaline phosphatase, glutamate dehydrogenase, and cholinesterase), the concentrations of electrolytes, glucose, urea, creatinine, triglycerides and cholesterol in serum, the total serum protein concentration, creatinine clearance as well as the concentrations of protein, electrolytes, glucose, ketones, haemoglobin, bilirubin, urobilinogen, nitrogen concentrations in urine, urine osmolarity, urine sediment, red and white blood cell count, and blood coagulation status were determined in the Institut für Klinische Chemie of the Medizinische Hochschule Hannover using standard techniques.
For distribution statistics and comparison of data, two-period-crossover analysis as described by Hecker with (%) and without (#) coadministration of diltiazem. [24 ] . This test is based on the comparison of differences of the observed values (m) between the two study periods (A,B) in the two groups (diltiazem in period 1 (m 1X ) or cyclosporine was 1.6 fold and that of the sum of all metabolites was 1.7 fold greater with than without 2 (m 2X )). The following effects were tested: diltiazem. Diltiazem modified the cyclosporine metabolite AUC (0, 12 h) values with an overproportional increase of the metabolites cyclised at
amino acid 1 such as AM1c (2.6 fold) and AM1c9 (2.2 fold) as well as the carboxylated cyclosporine metabolite AM1A (2.4 fold ). The increase of the AUC (0, 12 h) The differences were compared using the two-sided ttest. Distribution statistics was calculated using the SAS values of the hydroxylated and demethylated metabolites was in general less than 2-fold ( Table 2 ). The C max of Univariate procedure.
cyclosporine and that of the cyclised metabolite AM1c were significantly higher under diltiazem (Table 2) . Diltiazem had no significant effect on the time-to-peak concentration (t max ) or on the estimated terminal Results elimination half-lives (t 1/2,z ) of cyclosporine and its metabolites ( Table 2 ). The changes in cyclosporine The two-period crossover analysis failed to detect carryover or period effects. Metabolites AM14N, and AM4N metabolite patterns in blood were reflected in 12 h urine. The concentrations of cyclosporine and almost all its were not detected in blood. After diltiazem, the concentrations of cyclosporine and its metabolites were higher metabolites except the demethylated metabolites and the carboxylated metabolite AM1A were increased than without diltiazem (Figure 1 ). The AUC (0, 12 h) of under concomitant diltiazem administration (Table 3 ) . combination of diltiazem with cyclosporine led not only to an increase of the AUC of cyclosporine but of those The increase in metabolite concentrations in urine under diltiazem therapy was most prominent for the metabof several metabolites as well. The metabolite pattern was shifted with an over-proportional increase in olites AM1 (2.3 fold ), AM1c (3.2 fold ) and AM1c9 (4.6 fold).
cyclosporine metabolites cyclized at amino acid 1. Since cyclosporine and diltiazem are metabolized by the same Although the AUC(0, 12 h) values in male and female patients without diltiazem therapy were not different, CYP enzymes in the liver [12, 13] and diltiazem is a known inhibitor of the cyclosporine in vitro metabolism, the increase in AUC(0, 12 ) values of cyclosporine and its metabolites was more pronounced in female than in it can be assumed that diltiazem inhibited cyclosporine metabolism in the liver. This would explain the higher male patients (Table 4) . The difference of the AUC (0, 12 h) values of cyclosporine with and without diltiazem AUC values of cyclosporine in combination with diltiazem but not the parallel increase of the AUC was significantly higher in female than in male patients (P<0.02). The differences of the AUC (0, 12 h) values of values of its metabolites. Several studies in which pharmacokinetics after oral the metabolites, especially AM1c, tended to be higher in female patients as well (Table 4 ) . and intravenous administration of cyclosporine were compared, have raised evidence for pre-hepatic metabolism of cyclosporine. In vitro, small intestinal microsomes metabolised cyclosporine to its major metabolites [25, 26] and after installation of cyclosporine in the Discussion small intestine of an anhepatic patient, cyclosporine metabolites were found in the portal vein [27] . Kolars Several studies reported an increase in cyclosporine blood concentrations when the patients received diltiaet al. [ 26] showed that the metabolites formed in the small intestinal mucosa also reenter the lumen and this zem [17] [18] [19] [20] . Detailed analysis of the cyclosporine metabolite pattern in the present study showed that the way, metabolism in the small intestine may affect absorption of CYP3A substrates. In a clinical study, Hebert et al. [28 ] showed that CYP3A enzymes in the There is strong evidence that besides the main metabolic pathway of cyclosporine an alternative metato note that female patients under contraceptive therapy have been excluded from this study. The data available bolic pathway exists. CYP3A enzymes are responsible for hydroxylation and demethylation of cyclosporine to date are not sufficient to explain these differences. Analysis of the cyclosporine metabolite pattern [15 ] . It was assumed that cyclization of amino acid 1 with formation of a furan ring is a non-enzymatic showed that diltiazem increases the AUC values of cyclosporine and its metabolites and shifts the metabolite reaction [29, 30 ] . Meanwhile, several studies showed that cyclization is inducible by several CYP1A inducers pattern resulting in relatively higher concentrations of cyclosproine metabolites cyclized at amino acid 1. These such as methylcholanthrene and b-naphthoflavone [31, 32]. Prueksaritanont et al. [33] reported that CYP2C6 results can be explained by and support the impact of a significant influence of intestinal metabolism on cyclomight be involved in the cyclization of cyclosporine. The existence of an alternative cyclosporine metabolic sporine bioavailability and the existence of an alternative cyclosporine metabolic pathway. The results of this pathway was used to explain toxicity in patients with low CYP3A concentrations in the liver [34] and in study emphasize the need of a detailed analysis of the metabolite patterns in drug interaction studies with vitro the cyclized metabolite AM1c9 increases endothelin production by mesangial cells [35] . The modification cyclosporine. This aspect is especially important when drugs are combined with cyclosporine only to reduce of the cyclosporine metabolite pattern by diltiazem can be explained by such an alternative cyclosporine metathe cyclosporine doses required to maintain effective blood concentrations [37, 38] . An important result bolic pathway. While diltiazem partially inhibits the CYP3A-catalysed metabolism in the liver, the CYP which requires further evaluation with a larger number of patients is the gender-dependent changes of the enzymes responsible for cyclization are not affected. This results in a relatively higher formation rate of cyclosporine metabolite patterns in blood when diltiazem is co-administered. cyclized metabolites compared with hydroxylated and/or demethylated metabolites. cyclosporine doses covering in several cases less than the terminal half-life, the terminal half-lives had to be calculated by extrapolation of the fitted curves and thus represent only approximate values. References This study showed striking differences in the modification of cyclosporine metabolite patterns by co-
